← Shandong Buchang Pharmaceuticals overview

Shandong Buchang Pharmaceuticals vs Zhejiang Huahai Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shandong Buchang Pharmaceuticals Co Ltd (603858.CG)

Q3 202623 Jul – 9 Oct 2026

▲3▼1

Buchang's profit slump offsets steady pipeline and product expansion

Interim profit and cash flow tumble First-half 2026 revenue fell 11.67% to 5.0 billion yuan and net profit dropped 19.93% to 503 million yuan, while operating cash flow plunged 68.96%. Weaker earnings and cash generation weigh on the stock because they show the core business is shrinking.
This is the single biggest force pushing the stock down this period.
New drug approvals and filings broaden the product line Buchang won approval for Atomoxetine Hydrochloride Oral Solution for ADHD, had a new cancer indication for BC008-1A injection accepted for trials, and gained a license change to make an injectable drug. These add future revenue sources and support the stock.
Shows the pipeline progress that partly offsets the weak earnings.
Small deals add products and fund exposure A subsidiary bought the production approval and technology for Angong Niuhuang Wan for 9.4 million yuan, and Buchang put 100 million yuan into a healthcare equity fund. Both are modest but expand its product portfolio and investment reach.
These are the period's other concrete actions affecting the company's growth outlook.
Medical device development contracts signed A wholly owned subsidiary signed contracts to develop two Class III injectable medical devices for facial volume loss and jaw contour, owning all rights. This opens a new business area beyond drugs, though it is early-stage and years from revenue.
It is a new strategic move that could support longer-term growth.

August 202623 Jul – 9 Oct 2026

▲3▼1

Buchang's profit slump offsets steady pipeline and product expansion

Interim profit and cash flow tumble First-half 2026 revenue fell 11.67% to 5.0 billion yuan and net profit dropped 19.93% to 503 million yuan, while operating cash flow plunged 68.96%. Weaker earnings and cash generation weigh on the stock because they show the core business is shrinking.
This is the single biggest force pushing the stock down this period.
New drug approvals and filings broaden the product line Buchang won approval for Atomoxetine Hydrochloride Oral Solution for ADHD, had a new cancer indication for BC008-1A injection accepted for trials, and gained a license change to make an injectable drug. These add future revenue sources and support the stock.
Shows the pipeline progress that partly offsets the weak earnings.
Small deals add products and fund exposure A subsidiary bought the production approval and technology for Angong Niuhuang Wan for 9.4 million yuan, and Buchang put 100 million yuan into a healthcare equity fund. Both are modest but expand its product portfolio and investment reach.
These are the period's other concrete actions affecting the company's growth outlook.
Medical device development contracts signed A wholly owned subsidiary signed contracts to develop two Class III injectable medical devices for facial volume loss and jaw contour, owning all rights. This opens a new business area beyond drugs, though it is early-stage and years from revenue.
It is a new strategic move that could support longer-term growth.

Latest23 Jul – 9 Oct 2026

▲3▼1

Buchang's profit slump offsets steady pipeline and product expansion

Interim profit and cash flow tumble First-half 2026 revenue fell 11.67% to 5.0 billion yuan and net profit dropped 19.93% to 503 million yuan, while operating cash flow plunged 68.96%. Weaker earnings and cash generation weigh on the stock because they show the core business is shrinking.
This is the single biggest force pushing the stock down this period.
New drug approvals and filings broaden the product line Buchang won approval for Atomoxetine Hydrochloride Oral Solution for ADHD, had a new cancer indication for BC008-1A injection accepted for trials, and gained a license change to make an injectable drug. These add future revenue sources and support the stock.
Shows the pipeline progress that partly offsets the weak earnings.
Small deals add products and fund exposure A subsidiary bought the production approval and technology for Angong Niuhuang Wan for 9.4 million yuan, and Buchang put 100 million yuan into a healthcare equity fund. Both are modest but expand its product portfolio and investment reach.
These are the period's other concrete actions affecting the company's growth outlook.
Medical device development contracts signed A wholly owned subsidiary signed contracts to develop two Class III injectable medical devices for facial volume loss and jaw contour, owning all rights. This opens a new business area beyond drugs, though it is early-stage and years from revenue.
It is a new strategic move that could support longer-term growth.

Zhejiang Huahai Pharmaceutical Co Ltd (600521.CG)

Q3 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

August 202624 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.

Latest24 Jul – 7 Oct 2026

▲4

Huahai's profit surges on API growth, procurement wins, and US recovery

Q1-Q3 profit forecast up 170-190% Huahai expects net profit for the first three quarters of 2026 to jump 170%-190% to 1.03-1.10 billion yuan, driven by API market expansion, domestic procurement share gains, and a turnaround in US finished drug sales. This directly boosts investor confidence and the stock's earnings outlook.
This is the biggest new financial catalyst, showing a sharp profit increase that likely drives the stock price up.
Reciceptimab approved for market Huahai's first-in-class IL-36R antibody Reciceptimab (Huayijing) received marketing approval in China for generalized pustular psoriasis. This strengthens its innovative drug pipeline and opens a new revenue stream, supporting long-term growth and valuation.
A new drug approval is a concrete pipeline win that can lift future earnings and investor sentiment.
Won bids for 4 products in national procurement Huahai won bids for four products in China's 12th national drug procurement, three of which were newly approved in Q2 2026. Winning these bids helps quickly expand domestic hospital sales and market share, though price cuts are typical in such programs.
Procurement wins directly boost domestic sales volume and are a key growth driver cited in the profit forecast.
US tariff refunds and HB0043 trial approval Huahai received over $10 million in US IEEPA tariff refunds, adding a one-time profit boost. Separately, its subsidiary got clinical trial approval for HB0043, a world-first bispecific antibody for hidradenitis suppurativa, advancing its innovative pipeline.
These are new positive developments that improve cash flow and pipeline prospects, though smaller than the profit forecast.